10 known cases. View patent page →
Related patent-infringement action asserting the '517, '230, '740, '569, '357 and '219 patents; consolidated with the 2010 action by order dated November 9, 2012. The narrative could not confirm that the '554 patent was separately asserted in this 2012 action.
Celgene asserted U.S. 7,977,357 against Natco, Arrow, and Watson in a REVLIMID ANDA litigation. The case settled and a consent judgment entered Jan. 4, 2016 dismissed claims with prejudice and enjoined Natco from generic lenalidomide except under license. The May 27, 2014 Markman opinion in the Natco litigation also construed 'Form A' for the '357 and '598 patents.
Celgene sued Cipla over lenalidomide, and on Apr. 30, 2019 Cipla stipulated it would not contest infringement of the '357, '219, and '598 patents while reserving invalidity. The case was administratively terminated and consolidated into 2:19-cv-14731 on June 8, 2020, and ultimately settled Dec. 11, 2020.
Celgene obtained a consent judgment against Lotus and Alvogen in a REVLIMID ANDA case. The Mar. 29, 2019 judgment enjoined defendants from marketing ANDA No. 210480 until expiration of the patents-in-suit, which expressly included U.S. 7,977,357, and dismissed all claims with prejudice under a confidential settlement license.
Celgene and Sun settled a Hatch-Waxman lenalidomide action in July 2021. The asserted patents identified in the settlement were U.S. 7,977,357, 8,193,219, and 8,431,598, with volume-limited sales after March 2022 and unlimited after Jan. 2026; the Hatch-Waxman actions were dismissed.
D.N.J. action listed as family-flagged on the U.S. 7,977,357 patent record. Parties and whether the '357 patent itself was asserted were not confirmed.
Celgene's consolidated action against Cipla consolidated 2:17-cv-06163 and 2:18-cv-08964. It settled in Dec. 2020; the consolidated Cipla action carried the '357, '219, and '598 patents from 2:18-cv-08964.
Antitrust litigation in which purchasers/insurers allege Celgene's serial ANDA suits, including those asserting the '357, '219, and '598 Form A crystal patents, were sham litigation and that settlements were reverse payments. U.S. 7,977,357 features as one of the Form A crystal patents at issue, not as a direct infringement claim; the court issued a June 6, 2024 opinion on sham-litigation allegations.
Direct-purchaser opt-out antitrust case against Celgene. U.S. 7,977,357 is referenced in the narrative as part of the REVLIMID/THALOMID antitrust litigation context.
Antitrust case against Celgene listed with the REVLIMID/THALOMID matters referencing U.S. 7,977,357. No additional patents or dates were provided.